Maggie

Biotech enthusiast | Trader | Lifelong learner of markets & molecules.

[Srećko @ajdpali]

najbolja stvar kad prođe par godina pa zaboraviš seriju koja je bila top pa je pustiš ispočetka, izgleda da ćemo opet da gledamo kako se lezbe makljaju u zatvoru

[Maggie @BiotechLedger]

@Biotekster I was looking for u all these days

[Maggie @BiotechLedger]

@cryptofergani Me

[Maggie @BiotechLedger]

@vulturetrades I want to be part of this

[Maggie @BiotechLedger]

from the lake up to the moon #mltx 📈📈📈

[rwlk @sherlock_hodles]

Trump managing Iran, Israel and the S&P 500

[Maggie @BiotechLedger]

$MLTX UPDATE

– FDA allows BLA submission without new Phase 3 🔥
– Fast Track granted
– Multiple Phase 2/3 catalysts in 2026

This is classic biotech (which I love)
High risk. High reward.

2026 = make or break.

#biotech #stocks #MLTX

[Maggie @BiotechLedger]

EXACTLY

[Not Jerome Powell @alifarhat79]

Trump: I’m dropping a nuke on Iran tonight.

Iran: We’re going to wipe out the entire Middle East tonight.

Traders:

[kuno @kunoo]

Real 😂

[Steve Burns @SJosephBurns]

What it feels like trading in 2026:

[Maggie @BiotechLedger]

#mltx u better hurry up with bullish cause i need new fillers

[kuno @kunoo]

Real 😂

[Maggie @BiotechLedger]

@JerryLee2248 mltx didnt fail lol

[kuno @kunoo]

Real 😂

[Tooly @ToolySOL]

Built different.

[Biotech-ster @Biotekster]

$mltx

[Maggie @BiotechLedger]

@n_hatami Thank you appreciate it

[Maggie @BiotechLedger]

$IOVA is no longer just a story it has an FDA-approved product (Amtagvi) and real commercial execution ahead. Yes, the stock is volatile, but biotech rewards patience when science turns into revenue. Risk is high, but so is the asymmetry. Know what you hold.

[Maggie @BiotechLedger]

$ZNTL has extended cash runway into late 2027 and is progressing DENALI Part 2, with topline data on the horizon. High risk, but high asymmetric potential if clinical success and regulatory momentum continue. 🧬🚀